Skip to main content
Contact Us
Back to Homepage
follow us on linkedin
follow us on facebook
follow us on twitter
follow us on youtube
Investors
News
Events & Presentations
Financials
Quarterly Results
Annual Reports
SEC Filings
Interactive Financials
Form 8937
Stock Information
Stock Details
Analyst Coverage
Governance
Governance Documents
Committee Composition
Resources
Investor FAQs
Investor Email Alerts
Site Search
toggle main menu
News
Investors
News
Events & Presentations
Financials
Quarterly Results
Annual Reports
SEC Filings
Interactive Financials
Form 8937
Stock Information
Stock Details
Analyst Coverage
Governance
Governance Documents
Committee Composition
Resources
Investor FAQs
Investor Email Alerts
Normal
Press release year list
2022
2021
2020
2019
2018
2017
2016
2015
2014
06/08/2022
Marinus Pharmaceuticals Expands Enrollment Criteria to Support Recruitment in Phase 3 RAISE Trial in Refractory Status Epilepticus
Download
PDF format download (opens in new window)
06/03/2022
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Download
PDF format download (opens in new window)
05/18/2022
Marinus Pharmaceuticals to Present at Upcoming Medical and Investor Conferences
Download
PDF format download (opens in new window)
05/12/2022
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results
Download
PDF format download (opens in new window)
05/10/2022
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Download
PDF format download (opens in new window)
05/05/2022
Marinus Pharmaceuticals Announces Resumption of Phase 3 RAISE Trial in Status Epilepticus
Download
PDF format download (opens in new window)
04/20/2022
Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2022 Financial Results on May 12, 2022
Download
PDF format download (opens in new window)
04/18/2022
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Download
PDF format download (opens in new window)
04/14/2022
Marinus Pharmaceuticals Announces Publication in The Lancet Neurology of ZTALMY® (ganaxolone) Phase 3 Marigold Trial Results
Download
PDF format download (opens in new window)
03/31/2022
Marinus Pharmaceuticals Bolsters Financial Position With Drawdown of $30 Million Under Oaktree Capital Credit Facility
Download
PDF format download (opens in new window)
03/21/2022
Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
Download
PDF format download (opens in new window)
03/18/2022
Marinus Pharmaceuticals Announces FDA Approval of ZTALMY® (ganaxolone) for CDKL5 Deficiency Disorder
Download
PDF format download (opens in new window)
03/15/2022
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Download
PDF format download (opens in new window)
02/22/2022
Marinus Pharmaceuticals Announces Delay to RAISE Phase 3 Clinical Trial in Status Epilepticus and Associated IV Ganaxolone Clinical Trials
Download
PDF format download (opens in new window)
02/16/2022
Marinus Pharmaceuticals to Provide Business Update and Announce Preliminary Fourth Quarter 2021 Financial Results on March 21, 2022
Download
PDF format download (opens in new window)
02/10/2022
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Download
PDF format download (opens in new window)
02/03/2022
Marinus Pharmaceuticals Completes In Vivo M2 Metabolite Study and Provides European Regulatory Update
Download
PDF format download (opens in new window)
01/14/2022
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Download
PDF format download (opens in new window)
01/05/2022
Marinus Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference and H.C. Wainwright Bioconnect Conference
Download
PDF format download (opens in new window)